Figure 1
From: Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
sMUC16 binding to immune cells is reduced following neuraminidase treatment. PBMC from each of six ovarian cancer patients were digested with neuraminidase from Clostridium perfringens in phosphate buffered saline (PBS). Matching control PBMC from each of the six patients were treated with heat inactivated neuraminidase (Clostridium perfringens). sMUC16 binding to the control and enzymatically digested cells was measured by flow cytometry using the anti-MUC16 antibody, VK-8. Each bar is the mean measurement for all six donors. Data was analyzed using the Wilcoxon signed rank test.